Clinical trial
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
NCT00003102 · Ludwig Institute for Cancer Research, Other · Completed
Key facts
| NCT number | NCT00003102 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer |
| Official title | Phase I/II Study of 131I-Labeled Chimeric Antibody G250 (131I-cG250) in Patients With Advanced Renal Carcinoma |
| Lead sponsor | Ludwig Institute for Cancer Research, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Biological |
| Interventions | Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250) |
| Enrollment | 15 |
| Start date | Nov 17, 1998 |
| Primary completion | Apr 19, 2000 |
| Completion | May 27, 2003 |
| First posted | Aug 12, 2004 |
| Last update posted | Oct 4, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: